3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
10
Endocrine
2
CNS
2
Gynecologic
1
Breast
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Carcinoma, Renal Cell
1
Adenoma, Islet Cell
1
Interventions
lutetium Lu 177 dotatate
16
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
9
Specimen Handling
8
Everolimus
8
pembrolizumab
7
cabozantinib
6
Cisplatin
6
fluorodopa F 18
5
Etoposide
5
trametinib
4
surufatinib
4
lanreotide
4
dabrafenib
4
cemiplimab
4
X-Rays
4
Temozolomide
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
Fluorodeoxyglucose F18
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
olaparib
3
lenvatinib
3
copper dotatate CU-64
3
Transurethral Resection of Prostate
3
Thyrotropin Alfa
3
Surveys and Questionnaires
3
Somatostatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
belzutifan
×
Endocrine
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled